Immune checkpoint inhibitor–associated myocarditis: Case reports and a review of the literature

T. E. Osinga; S. F. Oosting; P. van der Meer; R. A. de Boer; B. C. Kuenen; A. Rutgers; L. Bergmann; T. H. Oude Munnink; M. Jalving; M. van Kruchten

doi:10.1007/s12471-021-01655-7

Immune checkpoint inhibitor–associated myocarditis: Case reports and a review of the literature

T. E. Osinga
, S. F. Oosting
, P. van der Meer
, R. A. de Boer
, B. C. Kuenen
, A. Rutgers
, L. Bergmann
, T. H. Oude Munnink
, M. Jalving
, M. van Kruchten^*

^*Corresponding author for this work

University Medical Centre Groningen
Martini Ziekenhuis
University Hospital

Research output: Contribution to journal › Review article › Academic › peer-review

16 Citations (Scopus)

Abstract

Immune checkpoint inhibitors (ICIs) are increasingly recognised to effectuate long-lasting therapeutic responses in solid tumours. However, ICI therapy can also result in various immune-related adverse events, such as ICI-associated myocarditis, a rare but serious complication. The clinical spectrum is wide and includes asymptomatic patients and patients with fulminant heart failure, making it challenging to diagnose this condition. Furthermore, the optimal diagnostic algorithm and treatment of ICI-associated myocarditis is unknown. In this review, we describe two cases on both ends of the spectrum and discuss the challenges in recognising, diagnosing and treating ICI-associated myocarditis.

Original language	English
Pages (from-to)	295-301
Number of pages	7
Journal	Netherlands Heart Journal
Volume	30
Issue number	6
DOIs	https://doi.org/10.1007/s12471-021-01655-7
Publication status	Published - Jun 2022
Externally published	Yes

Bibliographical note

Funding Information:
The University Medical Centre Groningen has received research grants and/or fees from AstraZeneca, Abbott, Bristol Myers Squibb (BMS), Novartis, Novo Nordisk and Roche. S. F. Oosting has received a research grant, which was paid to the institution, from Celldex and Novartis. R. A de Boer has received speaker fees from Abbott, AstraZeneca, Novartis and Roche. L. Bergmann has received a financial grant for a non-clear cell renal cell carcinoma clinical trial from BMS. M. Jalving has received advisory board honoraria, which were paid to the institution, from Merck, BMS, Novartis, Pierre Fabre, Tesaro and AstraZeneca, speaker’s fees from Sanofi and support for clinical studies from BMS, AbbVie, Merck and Cristal Therapeutics. T. E. Osinga, P. van der Meer, B. Kuenen, A. Rutgers, T. H. Oude Munnink and M. van Kruchten declare that they have no competing interests.

Publisher Copyright:
© 2022, The Author(s).

Access to Document

10.1007/s12471-021-01655-7

Cite this

@article{4571789e1e124f1aa288efb8f99208c7,

title = "Immune checkpoint inhibitor–associated myocarditis: Case reports and a review of the literature",

abstract = "Immune checkpoint inhibitors (ICIs) are increasingly recognised to effectuate long-lasting therapeutic responses in solid tumours. However, ICI therapy can also result in various immune-related adverse events, such as ICI-associated myocarditis, a rare but serious complication. The clinical spectrum is wide and includes asymptomatic patients and patients with fulminant heart failure, making it challenging to diagnose this condition. Furthermore, the optimal diagnostic algorithm and treatment of ICI-associated myocarditis is unknown. In this review, we describe two cases on both ends of the spectrum and discuss the challenges in recognising, diagnosing and treating ICI-associated myocarditis.",

author = "Osinga, \{T. E.\} and Oosting, \{S. F.\} and \{van der Meer\}, P. and \{de Boer\}, \{R. A.\} and Kuenen, \{B. C.\} and A. Rutgers and L. Bergmann and \{Oude Munnink\}, \{T. H.\} and M. Jalving and \{van Kruchten\}, M.",

note = "Funding Information: The University Medical Centre Groningen has received research grants and/or fees from AstraZeneca, Abbott, Bristol Myers Squibb (BMS), Novartis, Novo Nordisk and Roche. S. F. Oosting has received a research grant, which was paid to the institution, from Celldex and Novartis. R. A de Boer has received speaker fees from Abbott, AstraZeneca, Novartis and Roche. L. Bergmann has received a financial grant for a non-clear cell renal cell carcinoma clinical trial from BMS. M. Jalving has received advisory board honoraria, which were paid to the institution, from Merck, BMS, Novartis, Pierre Fabre, Tesaro and AstraZeneca, speaker{\textquoteright}s fees from Sanofi and support for clinical studies from BMS, AbbVie, Merck and Cristal Therapeutics. T. E. Osinga, P. van der Meer, B. Kuenen, A. Rutgers, T. H. Oude Munnink and M. van Kruchten declare that they have no competing interests. Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = jun,

doi = "10.1007/s12471-021-01655-7",

language = "English",

volume = "30",

pages = "295--301",

journal = "Netherlands Heart Journal",

issn = "1568-5888",

publisher = "Bohn Stafleu van Loghum",

number = "6",

}

TY - JOUR

T1 - Immune checkpoint inhibitor–associated myocarditis

T2 - Case reports and a review of the literature

AU - Osinga, T. E.

AU - Oosting, S. F.

AU - van der Meer, P.

AU - de Boer, R. A.

AU - Kuenen, B. C.

AU - Rutgers, A.

AU - Bergmann, L.

AU - Oude Munnink, T. H.

AU - Jalving, M.

AU - van Kruchten, M.

N1 - Funding Information: The University Medical Centre Groningen has received research grants and/or fees from AstraZeneca, Abbott, Bristol Myers Squibb (BMS), Novartis, Novo Nordisk and Roche. S. F. Oosting has received a research grant, which was paid to the institution, from Celldex and Novartis. R. A de Boer has received speaker fees from Abbott, AstraZeneca, Novartis and Roche. L. Bergmann has received a financial grant for a non-clear cell renal cell carcinoma clinical trial from BMS. M. Jalving has received advisory board honoraria, which were paid to the institution, from Merck, BMS, Novartis, Pierre Fabre, Tesaro and AstraZeneca, speaker’s fees from Sanofi and support for clinical studies from BMS, AbbVie, Merck and Cristal Therapeutics. T. E. Osinga, P. van der Meer, B. Kuenen, A. Rutgers, T. H. Oude Munnink and M. van Kruchten declare that they have no competing interests. Publisher Copyright: © 2022, The Author(s).

PY - 2022/6

Y1 - 2022/6

N2 - Immune checkpoint inhibitors (ICIs) are increasingly recognised to effectuate long-lasting therapeutic responses in solid tumours. However, ICI therapy can also result in various immune-related adverse events, such as ICI-associated myocarditis, a rare but serious complication. The clinical spectrum is wide and includes asymptomatic patients and patients with fulminant heart failure, making it challenging to diagnose this condition. Furthermore, the optimal diagnostic algorithm and treatment of ICI-associated myocarditis is unknown. In this review, we describe two cases on both ends of the spectrum and discuss the challenges in recognising, diagnosing and treating ICI-associated myocarditis.

AB - Immune checkpoint inhibitors (ICIs) are increasingly recognised to effectuate long-lasting therapeutic responses in solid tumours. However, ICI therapy can also result in various immune-related adverse events, such as ICI-associated myocarditis, a rare but serious complication. The clinical spectrum is wide and includes asymptomatic patients and patients with fulminant heart failure, making it challenging to diagnose this condition. Furthermore, the optimal diagnostic algorithm and treatment of ICI-associated myocarditis is unknown. In this review, we describe two cases on both ends of the spectrum and discuss the challenges in recognising, diagnosing and treating ICI-associated myocarditis.

UR - https://www.scopus.com/pages/publications/85123261421

U2 - 10.1007/s12471-021-01655-7

DO - 10.1007/s12471-021-01655-7

M3 - Review article

C2 - 35061242

AN - SCOPUS:85123261421

SN - 1568-5888

VL - 30

SP - 295

EP - 301

JO - Netherlands Heart Journal

JF - Netherlands Heart Journal

IS - 6

ER -

Immune checkpoint inhibitor–associated myocarditis: Case reports and a review of the literature

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this